Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
159 articles with Boehringer Ingelheim Pharmaceuticals, Inc.
8/17/2020It was a very busy week for clinical trial updates. Here’s a look.
Boehringer Ingelheim and Eli Lilly and Company announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
The approval was based on two randomized open-label clinical trials that evaluated the combination of empagliflozin, linagliptin and metformin and their individual components in healthy adults.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
Results were presented from the company’s pan-KRAS program including BI 1701963, which is being investigated alone and in combination with MEK inhibition in an ongoing Phase I clinical study in cancer patients
Boehringer Ingelheim, a global leader in veterinary rabies vaccines2, plans to donate 60,000 doses of its IMRAB® rabies vaccine for dogs over the next three years to fight rabies in Puerto Rico.
Boehringer Ingelheim and Lupin Limited announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound as a potential targeted therapy for patients with difficult-to-treat cancers.
Boehringer's global head of information technology, Michael Schmelmer, will replace Menne on Jan. 1, 2018.
Boehringer Ingelheim Initiates Real-World Study of Treatment Sequencing in EGFR Mutation-Positive Lung Cancer
The study, a retrospective review, will analyze data from 65 study centers in 11 countries to determine the time on treatment of afatinib as first-line therapy in EGFR mutation positive lung cancer followed by osimertinib for patients with T790M resistance mutation, in a real-world setting.
External partnerships complement Boehringer Ingelheim's two-pronged research strategy - investigating both cancer cell-directed therapies and immune cell-directed therapies.
HITGEN and Boehringer Ingelheim Enter DNA-Encoded Library Based Drug Discovery Research Collaboration
HitGen will receive upfront payments, and be eligible for milestone payments from Boehringer Ingelheim. Specific financial details were not disclosed.
11/27/2017Boehringer has made a big push into RNA this month.
BioMed X and Boehringer Ingelheim Start New Joint Research Group in Bacterial Modulation of Innate Immunity
The focus of the group will be to identify novel regulatory pathways within the innate immune system, through understanding molecular mechanisms employed by bacteria to evade or modulate innate immunity.
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com to Unlock Their Full Potential
The platform offers direct access to molecules for independent research as well as other molecules for partnering with Boehringer Ingelheim.
Boehringer Ingelheim's New RE-VERSE AD Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind) in Pradaxa Patients With GI Bleeding or Needing Emergency Surgery
The analyses provide further insights on the use of idarucizumab in patients with GI bleeding and in those with a need for urgent surgery or intervention.
Boehringer Ingelheim Release: Jardiance Reduced Risk of Cardiovascular Death in Adults With Type 2 Diabetes and Peripheral Artery Disease
hese results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly at the AHA Scientific Sessions 2017 in Anaheim, Calif. and simultaneously published online in the AHA's journal, Circulation.
Results From Boehringer Ingelheim's Six-Month Lung Imaging Study Showed Slowing of Fibrotic Progression in Patients With IPF Treated With Ofev Versus Placebo
The results are being presented at the PFF Summit 2017, November 9-11 in Nashville, Tenn.
CellSight Technologies Announces Strategic Collaboration With Boehringer Ingelheim to Develop a New Technology for Monitoring Anti-Tumor T-Cell Activation
The focus of the trial is to determine if early PET scans, at 6-12 weeks after the initial anti-PD1 inhibitor therapy dose, with the VisAcT tracer are predictive of response to immunotherapy.
Fresh off the heels of a $201M liver disease R&D deal with Dicerna, Boehringer Ingelheim has struck another deal targeting liver disease with MiNA Therapeutics.
Boehringer Ingelheim's Efficacy and Safety Maintained in Patients Who Switched From Humira to Biosimilar Cyltezo
The 48-week data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active RA, including in patients who switched from Humira to Cyltezo at week 24.